Is AI Drug Discovery Actually Working? What the 2026 Clinical Trial Data Shows
Dr. Dereck Mush, MD, MBA
Owkin
Applies federated learning and AI to biological data for drug discovery and diagnostics.
What they do
Owkin utilizes federated machine learning to analyze decentralized patient data without compromising privacy. Pharmaceutical enterprises and academic medical centers use this platform to discover novel cancer therapies, optimize clinical trial design, and develop advanced diagnostic tools for oncology and immunology.
The record
- Vertical
- Oncology
- Sub-segment
- AI drug discovery
- Product type
- Platform software
- Stage
- Series C+
- Headquarters
- Paris, France
- Region
- Europe
- Founded
- 2016
- Total funding
- $304M raised
Notable investors: Sanofi, Mubadala Investment Company, BPIFrance, Cathay Innovation.
Also in Oncology
Related on The Signal
Dr. Dereck Mush, MD, MBA
What Pharma Is Buying From AI Drug Discovery: Inside AstraZeneca’s insitro Deal
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA
AI is moving upstream, from molecule design into disease target identification itself
Dr. Dereck Mush, MD, MBA